EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Effectiveness and Safety of Ivabradine in Chinese Patients with Chronic Heart Failure: An Observational Study

Jingmin Zhou, Yamei Xu, Zhaofen Zheng, Shuyang Zhang, Jiefu Yang, Yuhui Zhang, Baopeng Tang, Huiyuan Han, Qing Zhang, Fan Liu, Wenhui Ding, Caizhen Qian und 15 weitere

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14581 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Jingmin Zhou und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China. Hauptthemen laut MEDLINE: Cardiovascular Agents, Heart Failure, Vision Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Servier, China, Servier.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

A therapeutic strategy for chronic heart failure (HF) is to lower resting heart rate (HR). Ivabradine is a well-known HR-lowering agent, but limited prospective data exist regarding its use in Chinese patients. This study aimed to evaluate the effectiveness and safety of ivabradine in Chinese patients with chronic HF. Methods and results This multicentre, single-arm, prospective, observational study enrolled Chinese patients with chronic HF. The primary outcome was change from baseline in HR at 1 and 6 months, measured by pulse counting. Effectiveness was also evaluated using laboratory tests, the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (CSS) and overall summary score (OSS), and New York Heart Association (NYHA) class. Treatment-emergent adverse events (TEAEs) were assessed. A post hoc analysis examined the effectiveness and safety of ivabradine combined with an angiotensin receptor–neprilysin inhibitor (ARNI) or beta-blocker. A total of 1003 patients were enrolled [mean age 54.4 ± 15.0 years, 773 male (77.1%), mean baseline HR 88.5 ± 11.3 b.p.m., mean blood pressure 115.7/74.4 ± 17.2/12.3 mmHg, mean left ventricular ejection fraction 30.9 ± 7.6%, NYHA Classes III and IV in 48.8% and 22.0% of patients, respectively]. HR decreased by a mean of 12.9 and 16.1 b.p.m. after 1 and 6 months, respectively (both P < 0.001). At Month 6, improvements in the KCCQ CSS and OSS of ≥5 points were observed in 72.1% and 74.1% of patients, respectively (both P < 0.001). Left ventricular ejection fraction increased by 12.1 ± 11.6 (P < 0.001), and 66.7% of patients showed improvement in NYHA class (P < 0.001). At Month 6, the overall proportion of patients in NYHA Classes III and IV was reduced to 13.5% and 2.1%, respectively. Serum brain natriuretic peptide (BNP) and N-terminal pro-BNP changed by −331.9 ng/L (−1238.6, −134.0) and −1113.8 ng/L (−2202.0, −297.2), respectively (P < 0.001). HR reductions and improvements in NYHA and KCCQ scores with ivabradine were similar with and without use of ARNIs or beta-blockers. Of 498 TEAEs in 296 patients (29.5%), 73 TEAEs in 55 patients (5.5%) were considered related to ivabradine [most frequent sinus bradycardia (n = 7) and photopsia (n = 7)]. TEAEs were reported in a similar number of patients in ARNI and beta-blocker subgroups (21.9–35.6%).

Conclusions

Ivabradine treatment reduced HR and improved cardiac function and health-related quality of life in Chinese patients with chronic HF. Benefits were seen irrespective of whether or not patients were also taking ARNIs or beta-blockers. Treatment was well tolerated with a similar profile to previous ivabradine studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular AgentsHeart FailureVision DisordersAdultAgedHumansMaleMiddle AgedAdrenergic beta-AntagonistsBenzazepinesChinaIvabradineProspective StudiesQuality of LifeStroke VolumeTreatment OutcomeVentricular Function, LeftFemale

Stichwörter der Autor:innen

Heart failureHeart rateIvabradineReal world

Substanzen

Adrenergic beta-AntagonistsBenzazepinesCardiovascular AgentsIvabradine

Autor:innen und Institutionen

  • Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China.
  • Hunan Provincial People's Hospital, Changsha, China.
  • Peking Union Medical College Hospital, Beijing, China.
  • Beijing Hospital, Beijing, China.
  • Fuwai Hospital, CAMS PUMC, Beijing, China.
  • The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

ORCID-Profile: Junbo Ge

Förderung

  • Servier, China
  • Servier

Zitieren

APA

Zhou, J., Xu, Y., Zheng, Z., Zhang, S., Yang, J., Zhang, Y., Tang, B., Han, H., Zhang, Q., Liu, F., Ding, W., Qian, C., Su, G., Liu, X., Shen, Y., Shi, B., Kong, X., Ge, Z., Zhang, P., …, & POSITIVE investigators (2024). Effectiveness and Safety of Ivabradine in Chinese Patients with Chronic Heart Failure: An Observational Study. ESC Heart Failure. https://doi.org/10.1002/ehf2.14581

Vancouver

Zhou J, Xu Y, Zheng Z, Zhang S, Yang J, Zhang Y, et al. Effectiveness and Safety of Ivabradine in Chinese Patients with Chronic Heart Failure: An Observational Study. ESC Heart Failure. 2024. doi:10.1002/ehf2.14581

BibTeX
@article{Zhou2024,
  author = {Zhou, Jingmin and Xu, Yamei and Zheng, Zhaofen and Zhang, Shuyang and Yang, Jiefu and Zhang, Yuhui and Tang, Baopeng and Han, Huiyuan and Zhang, Qing and Liu, Fan and Ding, Wenhui and Qian, Caizhen and Su, Guohai and Liu, Xiaohui and Shen, Yuansheng and Shi, Bei and Kong, Xiangqing and Ge, Zhiming and Zhang, Ping and Guo, Xiaomei and Zhang, Hong and Sun, Yuemin and Dong, Yugang and Fu, Guosheng and Feng, Lei and Ge, Junbo and POSITIVE investigators, POSITIVE investigators},
  title = {Effectiveness and Safety of Ivabradine in Chinese Patients with Chronic Heart Failure: An Observational Study},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14581}
}
Kostenlos starten →